Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a sell rating to a hold rating in a research report released on Wednesday morning.

ENTA has been the subject of several other research reports. HC Wainwright dropped their price target on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a buy rating for the company in a research report on Tuesday. JPMorgan Chase & Co. dropped their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating for the company in a report on Thursday, February 8th. Finally, JMP Securities cut their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a market outperform rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of Hold and a consensus price target of $19.00.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock opened at $12.76 on Wednesday. The business has a 50-day moving average of $14.88 and a 200 day moving average of $12.08. The stock has a market capitalization of $269.95 million, a PE ratio of -2.04 and a beta of 0.54. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $28.25.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The company had revenue of $18.00 million for the quarter, compared to analysts’ expectations of $22.74 million. Analysts anticipate that Enanta Pharmaceuticals will post -4.9 EPS for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its position in Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,281 shares in the last quarter. Clearstead Advisors LLC purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $57,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $118,000. Quantbot Technologies LP grew its stake in Enanta Pharmaceuticals by 2,300.0% in the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 6,900 shares during the period. Finally, Sherbrooke Park Advisers LLC bought a new position in Enanta Pharmaceuticals in the third quarter worth $113,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.